What are the recommended dosing regimens for estrogen and progesterone therapy in a postmenopausal woman with an intact uterus?

Recommended Dosing for Estrogen and Progesterone in Postmenopausal Women with Intact Uterus

For postmenopausal women with an intact uterus, use oral conjugated equine estrogens 0.625 mg daily or transdermal estradiol 50-100 µg twice weekly, combined with oral micronized progesterone 200 mg daily (continuous regimen) or 12-14 days per month (sequential regimen), with transdermal estrogen preferred for women with VTE risk, hypertension, hypertriglyceridemia, obesity, or diabetes. 1

Estrogen Dosing

Oral Estrogen Options

• Conjugated equine estrogens (CEE): 0.625 mg/day is the most extensively studied dose 1
• Oral micronized estradiol: 1 mg/day is commonly used 1
• Oral estrogens produce 5-fold higher estrone levels and 10-20 fold higher estrone sulfate compared to transdermal formulations, though the clinical significance remains unclear 1

Transdermal Estrogen Options (Preferred)

• Transdermal estradiol patches: 50-100 µg twice weekly 1
• Percutaneous gels, sprays, or emulsions: Equivalent dosing to patches 1
• Transdermal delivery avoids first-pass hepatic metabolism, reducing procoagulant effects, increases in SHBG, triglycerides, and inflammatory markers like C-reactive protein 1

Transdermal estrogen is specifically preferable for women with:

• History of VTE or VTE risk factors
• Hypertension
• Hypertriglyceridemia
• Obesity or metabolic syndrome
• Diabetes
• History of gallbladder disease 1

Vaginal Systemic Estrogen

• Estradiol acetate vaginal rings: 50-100 µg daily, replaced every 3 months, provide systemic levels requiring progestogen protection 1

Progesterone Dosing for Endometrial Protection

Critical principle: All women with an intact uterus receiving systemic estrogen MUST receive adequate progestogen to prevent endometrial hyperplasia and cancer. 1, 2

Continuous Combined Regimen (Preferred for Most Women)

• Oral micronized progesterone: 200 mg daily (though not explicitly stated in guidelines, this is standard practice)
• Medroxyprogesterone acetate (MPA): Minimum 1.5 mg daily 2
• Norethisterone acetate (NETA): Minimum 1 mg daily 2
• This regimen eventually produces amenorrhea in most women and is preferred for women more than 1-2 years postmenopausal 1

Sequential Regimen

• Progestogen duration: 12-14 days per month minimum 1, 3
• Administer estrogen for 20-25 days with progestogen for 12-15 days each month 1
• This approach is preferred for recently menopausal women prone to breakthrough bleeding during the first 1-2 years 1

Critical warning: Progestogen for less than 10 days per month is INSUFFICIENT and cannot be recommended 3. The 2021 ELITE trial demonstrated that even 10 days of vaginal progesterone 45 mg/day was inadequate to oppose oral estradiol 1 mg/day, resulting in progressive endometrial thickening and higher rates of endometrial hyperplasia 4.

Routes of Progestogen Administration

• Oral (most studied)
• Transdermal patch
• Vaginal (requires higher doses and longer duration than traditionally used)
• Intrauterine levonorgestrel device (minimizes systemic absorption but may increase breast cancer risk per one observational study) 1

Important Clinical Caveats

Unopposed Estrogen Risk

Unopposed estrogen at ANY dose and duration between 1-3 years significantly increases endometrial hyperplasia risk 2. This is non-negotiable—never prescribe systemic estrogen without progestogen in women with a uterus.

Vaginal Progesterone Concerns

The vaginal route requires careful consideration. The ELITE trial showed 10 days monthly of vaginal progesterone 45 mg was insufficient 4, while one smaller study suggested continuous vaginal progesterone 3-5 days weekly with transdermal estrogen may provide adequate protection 5. Given conflicting data, oral progestogen remains the gold standard for endometrial protection.

Bleeding Patterns

• Sequential regimens: Expect withdrawal bleeding
• Continuous combined: 51% of women experience spotting at 6 months, but 91.7% achieve amenorrhea by 1 year 6
• Bleeding on continuous regimens requires endometrial evaluation if persistent beyond 6-12 months

Dose Titration

Start with standard doses and titrate down to the lowest effective dose for symptom control 1. For women with premature menopause, higher starting doses (e.g., transdermal estradiol 100 µg) may be needed, then slowly lowered as tolerated 1.

FDA-Approved Products Only

Use FDA-approved preparations, not custom-compounded "bioidentical" hormones, which lack safety and efficacy data 1, 7.